: A randomized, placebo-controlled trial of the safety and efficacy of tecovirimat for the treatment of patients with monkeypox virus disease

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N91019D00024-P00001-759102000025-5

Grant search

Key facts

  • Disease

    mpox
  • Start & end year

    2020
    2025
  • Known Financial Commitments (USD)

    $9,824,009
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    LORI DODD
  • Research Location

    United States of America
  • Lead Research Institution

    LEIDOS BIOMEDICAL RESEARCH, INC.
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

  • Mpox Research Priorities

    Therapeutics research, development and implementation

  • Mpox Research Sub Priorities

    Development of equitable, accessible, safe & effective therapeutics

Abstract

The funding supports a clinical trial to identify effective treatments for monkeypox virus disease. Monkeypox virus is a re-emerging pathogen that causes monkeypox virus disease, a disease of epidemic potential that causes significant morbidity and can result in death. Human monkeypox cases have been increasing in sub-Saharan Africa since 2000 and sporadic outbreaks outside of Africa have occurred, with cases in the US and the UK in 2021. The similarity between MPXV and the variola virus, coupled with concerns about the potential of the variola virus as a potential bioterrorism agent, have placed monkeypox treatments at the forefront of public health and scientific research agendas in many countries.